XFOR Quote, Financials, Valuation and Earnings

Altimmune, Inc. has a net margin of -1689.24% compared to X4 Pharmaceuticals, Inc.'s net margin of -380280%. X4 Pharmaceuticals, Inc.'s return on equity of -279.19% beat Altimmune, Inc.'s return on equity of -56.24%.

X4 Pharmaceuticals, Inc. has a consensus price target of $8.00, signalling upside risk potential of 81%. On the other hand Altimmune, Inc. has an analysts' consensus of $17.75 which suggests that it could grow by 343.75%. Given that Altimmune, Inc. has higher upside potential than X4 Pharmaceuticals, Inc., analysts believe Altimmune, Inc. is more attractive than X4 Pharmaceuticals, Inc..

X4 Pharmaceuticals, Inc. has a beta of 0.421, which suggesting that the stock is 57.861% less volatile than S&P 500. In comparison Altimmune, Inc. has a beta of -0.029, suggesting its less volatile than the S&P 500 by 102.89%.

X4 Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Altimmune, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. X4 Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Altimmune, Inc. pays out -- of its earnings as a dividend.

X4 Pharmaceuticals, Inc. quarterly revenues are $1.8M, which are larger than Altimmune, Inc. quarterly revenues of $5K. X4 Pharmaceuticals, Inc.'s net income of -$29.8M is lower than Altimmune, Inc.'s net income of -$19M. Notably, X4 Pharmaceuticals, Inc.'s price-to-earnings ratio is 0.70x while Altimmune, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for X4 Pharmaceuticals, Inc. is 2.09x versus 15,885.21x for Altimmune, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -1689.24% compared to X4 Pharmaceuticals, Inc.'s net margin of 21.32%. X4 Pharmaceuticals, Inc.'s return on equity of -279.19% beat Pfizer Inc.'s return on equity of 10.84%.

X4 Pharmaceuticals, Inc. has a consensus price target of $8.00, signalling upside risk potential of 81%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.36%. Given that X4 Pharmaceuticals, Inc. has higher upside potential than Pfizer Inc., analysts believe X4 Pharmaceuticals, Inc. is more attractive than Pfizer Inc..

X4 Pharmaceuticals, Inc. has a beta of 0.421, which suggesting that the stock is 57.861% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.

X4 Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.87% to investors and pays a quarterly dividend of $0.43 per share. X4 Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

X4 Pharmaceuticals, Inc. quarterly revenues are $1.8M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. X4 Pharmaceuticals, Inc.'s net income of -$29.8M is lower than Pfizer Inc.'s net income of $3.6B. Notably, X4 Pharmaceuticals, Inc.'s price-to-earnings ratio is 0.70x while Pfizer Inc.'s PE ratio is 14.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for X4 Pharmaceuticals, Inc. is 2.09x versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Quantum-Si, Inc. has a net margin of -1689.24% compared to X4 Pharmaceuticals, Inc.'s net margin of -6467.94%. X4 Pharmaceuticals, Inc.'s return on equity of -279.19% beat Quantum-Si, Inc.'s return on equity of -51.75%.

X4 Pharmaceuticals, Inc. has a consensus price target of $8.00, signalling upside risk potential of 81%. On the other hand Quantum-Si, Inc. has an analysts' consensus of $2.68 which suggests that it could grow by 104.83%. Given that Quantum-Si, Inc. has higher upside potential than X4 Pharmaceuticals, Inc., analysts believe Quantum-Si, Inc. is more attractive than X4 Pharmaceuticals, Inc..

X4 Pharmaceuticals, Inc. has a beta of 0.421, which suggesting that the stock is 57.861% less volatile than S&P 500. In comparison Quantum-Si, Inc. has a beta of 2.983, suggesting its more volatile than the S&P 500 by 198.267%.

X4 Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quantum-Si, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. X4 Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Quantum-Si, Inc. pays out -- of its earnings as a dividend.

X4 Pharmaceuticals, Inc. quarterly revenues are $1.8M, which are larger than Quantum-Si, Inc. quarterly revenues of $552K. X4 Pharmaceuticals, Inc.'s net income of -$29.8M is higher than Quantum-Si, Inc.'s net income of -$35.7M. Notably, X4 Pharmaceuticals, Inc.'s price-to-earnings ratio is 0.70x while Quantum-Si, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for X4 Pharmaceuticals, Inc. is 2.09x versus 74.35x for Quantum-Si, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals, Inc. has a net margin of -1689.24% compared to X4 Pharmaceuticals, Inc.'s net margin of -3135.32%. X4 Pharmaceuticals, Inc.'s return on equity of -279.19% beat Recursion Pharmaceuticals, Inc.'s return on equity of -80.23%.

X4 Pharmaceuticals, Inc. has a consensus price target of $8.00, signalling upside risk potential of 81%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 59.09%. Given that X4 Pharmaceuticals, Inc. has higher upside potential than Recursion Pharmaceuticals, Inc., analysts believe X4 Pharmaceuticals, Inc. is more attractive than Recursion Pharmaceuticals, Inc..

X4 Pharmaceuticals, Inc. has a beta of 0.421, which suggesting that the stock is 57.861% less volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

X4 Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. X4 Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

X4 Pharmaceuticals, Inc. quarterly revenues are $1.8M, which are smaller than Recursion Pharmaceuticals, Inc. quarterly revenues of $5.2M. X4 Pharmaceuticals, Inc.'s net income of -$29.8M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$162.3M. Notably, X4 Pharmaceuticals, Inc.'s price-to-earnings ratio is 0.70x while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for X4 Pharmaceuticals, Inc. is 2.09x versus 40.36x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.